Celgene Says FDA Grants Priority Review For Fedratinib NDA In Myelofibrosis

Celgene Corp. (CELG) said Tuesday that the U.S. Food and Drug Administration has accepted the company's New Drug Application or NDA for Fedratinib and granted a Priority Review.

from RTT - Biotech https://ift.tt/2tP7V8H
via IFTTT